Get the Stockscreener App
178.49
5.70%
-10.79
After Hours:
179.40
0.91
+0.51%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $178.49, with a volume of 6.65M.
It is down -5.70% in the last 24 hours and down -2.69% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$189.28
Open:
$173.45
24h Volume:
6.65M
Relative Volume:
3.27
Market Cap:
$276.82B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
53.61
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-8.54%
1M Performance:
-2.69%
6M Performance:
+88.58%
1Y Performance:
+152.03%
1-Day Range:
$172.76
$180.21
1-Week Range:
$172.76
$193.79
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
178.49 | 293.55B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,216.95 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.10 | 634.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
249.91 | 446.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.07 | 311.17B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.62 | 296.08B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca wins appeal in Pfizer patent dispute over Tagrisso By Investing.com - Investing.com Nigeria
AstraZeneca Extends Anifrolumab Access With New ROSY-S Rollover Study - TipRanks
FTSE 100 held back by AstraZeneca trial setback - Yahoo Finance UK
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains - marketscreener.com
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure - Clinical Trials Arena
UK Stocks Drop as AstraZeneca's Heart Drug Trial Results, Geopolitical Tensions Weigh - marketscreener.com
Sino and AstraZeneca sign licence agreement for TQC3721 - Pharmaceutical Technology
AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis - TradingKey
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study - Yahoo Finance
AstraZeneca Shares Dive on Rare Trial Failure of Heart Drug - Bloomberg.com
ASTRAZENECA : Jefferies keeps its Buy rating - marketscreener.com
AstraZeneca stock holds steady on its global pipeline - Ad-hoc-news.de
AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns - Proactive financial news
ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com
AstraZeneca (AZN) Stock Plunges 9% as Wainua Trial Misses Primary Endpoint - Blockonomi
AstraZeneca, Ionis drug fails big heart disease study in major setback - BioPharma Dive
Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today?AstraZeneca (NYSE:AZN), Ionis Pharmaceu - Benzinga
AstraZeneca Cardiomyopathy Drug Wainua Fails to Meet Late-Stage Clinical Trial Goal as Shares Plunge Over 8% Pre-Market. - TradingKey
Breakfast News: AstraZeneca's Heart Drug Flatlines - The Motley Fool
AstraZeneca stock drops 9% after Wainua heart drug trial fails - Yahoo Finance
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags - marketscreener.com
AstraZeneca licenses Sino's COPD drug for $2.1bn - BioXconomy
ASTRAZENECA : Buy rating from Goldman Sachs - marketscreener.com
AstraZeneca sees stock market value slump by more than £20bn after drug setback - Yahoo Finance UK
AstraZeneca plc focuses on long-term growth. Oncology and vaccines underpin its strategy - Ad-hoc-news.de
Wainua heart trial misses primary endpoint for AstraZeneca (NYSE: AZN) - Stock Titan
ASTRAZENECA : Buy rating from Jefferies - marketscreener.com
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Tria - GuruFocus
AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint - Yahoo Finance UK
Ionis, AstraZeneca Report Amyloid Cardiomyopathy Treatment Failed to Meet Primary Endpoint in Phase 3 - marketscreener.com
AstraZeneca shares slump after clinical trial fails - marketscreener.com
FTSE 100 lags Europe as AstraZeneca sinks - marketscreener.com
AstraZeneca's Baxfendy Set For Blockbuster Sales After Hypertension Approval - Seeking Alpha
AstraZeneca shares fall 9% as cardiovascular drug Wainua fails test - marketscreener.com
AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial - Proactive financial news
AstraZeneca tumbles as heart drug trial misses main efficacy goal (AZN:NYSE) - Seeking Alpha
AstraZeneca tumbles, Schott Pharma raises its ambitions - marketscreener.com
The failure of a clinical trial sends AstraZeneca shares tumbling - marketscreener.com
AstraZeneca drops 9% on disappointing heart trial - Breakingthenews.net
AstraZeneca shares slide 9% after heart treatment disappoints in trial - Financial Times
AstraZeneca’s Wainua Falls Short in Phase III ATTR-CM Study Despite Positive Subgroup Signal (AVG) - Yahoo Finance UK
AstraZeneca And Ionis’ Wainua Misses Phase III ATTR-CM Trial Endpoint - DirectorsTalk Interviews
REGAstraZeneca PLCUpdate on CARDIO-TTRansform Phase III trial - TradingView
AstraZeneca Employee Traded On Icosavax Deal, SEC Says - Law360
AstraZeneca (AZN) Receives FDA Orphan Designation for Kidney Dis - GuruFocus
AstraZeneca (AZN) officer receives share grant via incentive plan - Stock Titan
Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News
AstraZeneca’s HELIOS Rare Disease Study Halted: What Investors Should Know - TipRanks
AstraZeneca, GSK intensify China ties with Sino Biopharm deals - BioPharma Dive
Sino Biopharma Accelerates Global Growth With GSK, AstraZeneca Partnerships - Benzinga
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):